2. Epidemiology
⢠Most common diagnosed Cancer worldwide
⢠1.8 million new cases yearly diagnosed globally
out of which 1.5million deaths
⢠13% of global cancer burden
⢠Highest incidence in Hungary(51/100000/yr)
⢠Incidence increasing in India and China
⢠6.9% of all new cancers
⢠9.3% of all cancer related death in india
⢠Incidence in India 28/100000
3. Presentation- Incidence
⢠Till 40 yrs; M=F
⢠50-70 years; M>F because of smoking habits
⢠Women âYounger, localized, Adenocarcinoma
⢠SCLC-Most cases 60-80 Yrs
⢠Smokers
5. Symptoms and signs
⢠Cough-Dry/Productive
⢠Chest pain
⢠Shortness of breath
⢠Coughing up blood
⢠Wheezing
⢠Hoarseness
⢠Recurring infections such as bronchitis and
pneumonia
⢠Weight loss and loss of appetite
⢠Fatigue
8. CLASSIFICATION OF CA LUNG
⢠Small cell lung carcinoma(oat cell
carcinoma):15%
⢠Non-small cell lung carcinoma:80-85%: 3 types
-Adenocarcinoma
-Squamous cell carcinoma
-Large cell carcinoma
9.
10.
11. Staging system
⢠History and physical
examination
⢠Chest radiography
⢠Sputum cytology
⢠CT
⢠PET
⢠Bone scan
⢠MRI
⢠Bronchoscopy
⢠Endobronchial USG
⢠Percutaneous
transthoracic needle
biopsy
⢠Cervical Mediastinoscopy
⢠Left ant. Mediastinotomy
and Extended cervical
Mediastinoscopy
⢠Scalene node biopsy
⢠VATS
⢠Thoracotomy
12. Staging
⢠AJCC and UICC 7th edition:2007
⢠IASLC(International association for the study
of lung cancer)
⢠cTNM /pTNM
13.
14. AJCC and UICC⢠TX-Primary can not be assessed
⢠T0-no evidence of primary tumor
⢠T is-carcinoma in situ
⢠T1a-tumor</=2cm
⢠T1b->2cm but </=3cm
⢠T2a->3cm but</=5cm
⢠T2b->5cm but </=7cm
⢠T3->7cm or invading chest wall
⢠T4-any size invading heart, RLN,
esophagus
⢠NX-regional lymph nodes cannot be
assessed
⢠N0-no regional lymph node metastasis
⢠N1-metastasis to I/L peribronchial, hilar,
intra pulmonary nodes.
⢠N2-Metastasis in I/L mediastinal or
subcarinal lymph nodes
⢠N3-metastasis in C/L medistinal hilar , I/L
or C/L scalene or supraclavicular lymph
nodes.
⢠MX-metastasis cannot be assessed
⢠M0-no distant metastasis
⢠M1a-sep. tumor nodule in C/L lobe tumor
with Pleural nodules or malignent pleural
effusion.
⢠M1b-distant metastasis
15.
16. Metastatic workup
⢠Metastatic sign and
symptoms:
⢠Bone pain
⢠Spinal cord impingement
⢠Neurological sign and
symptoms may include
the following:
Headache
Weakness or numbness of
limbs
Dizziness and
Seizures
⢠Bone scan
⢠MRI
⢠CT scan
⢠Tumor markers-NSCLC-
TPS,CYFRA-21-1,CEA
⢠SCLC-NSE
18. Lobectomy
⢠Lobectomy with complete en bloc tumor removal
remains the std. in pt. with resectable NSCLC.
⢠Position: Lateral decubitus
⢠Incision: Posterolateral
⢠Mobilization- hilar dissection
⢠Management of vessels(Auto suture GIA stapler /
electrocautry /ligatures).Order of division: PA, Vein,
bronchus
⢠Management of bronchus: Hand suturing tecnique,
stapler
⢠Placement of chest tubes: Apical, Basal
19. Sublobar resection
⢠NSCLC pt. who cannot tolerate anatomical lobectomy.
⢠Anatomical segmentectomy: Early stage NSCLC at low risk,
poor CP reserve.(Procedure of choice)
⢠Landmark is diseased bronchus, identification is key step
⢠Segmental vein divided last after identification of
intersegmental plane
⢠4-0 PDS ,absorbable interrupted suturing for bronchial
closure. (Inflation-Deflation tecnique)
⢠Stapling may be performed if sufficient length of diseased
segmental bronchus is available.
⢠Wedge resection :for small ,peripheral ,early stage NSCLC.
often accomplished by VATS
20. Pneumonectomy
⢠Reserved for central lesions, Good CP reserve
⢠Incision: Posterolateral thoracotomy via 5th ICS
⢠Hilar dissection(Double ligation/Stapling)
⢠Management of bronchus(Avoid BPF)
⢠Management of postpneumonectomy space:
chest tube/Pleur-Evac(drainage system)
â Avoid negative pressure
21. Mediastinal lymph node dissection
⢠Gold std. for staging
⢠Integral part of the surgical treatment of lung
cancer to determine accurate nodal status.
⢠Intra-operative frozen section
⢠Lymph node sampling (Hilar/Mediastinal L.N)
ďą Systemic sampling
ďą Complete lymph node dissection
ďą Extended lymph node dissection
22. Surgical treatment of NSCLC
⢠Mainly for Stage I or stage II NSCLC
⢠Stage IIIA and IIIB :Chemo-radiotherapy
â Heterogenous group, selected patients
ď§ Decision depends upon:
ď§ Extent of disease
ď§ Age
ď§ CP reserve
ď§ Performance status
ď§ Comorbid risk factors
23. Surgical treatment of NSCLC (T1&T2)
⢠Lobectomy>Sublobar resection>SBRT
⢠Three fold increase in incidence of local recurrence in
patients treated by resection smaller than lobectomy.
⢠Sublobar resection can be performed on patients with
small, peripheral ,early-stage NSCLC without
jeopardizing the clinical outcome.
⢠Key factors to obtain optimal result with
segmentectomy are:
â Surgical margins
â Tumor size
â lymph node assessment
24. T3
⢠NSCLC involving the chest wall but without
mediastinal node disease are good candidates for
surgical treatment
⢠Superior sulcus tumors: Combined modality
,induction chemoradiotherapy followed by
surgery
⢠Tumor in proximity of carina: Sleeve lobectomy
⢠Tumors invading mediastinum or diaphragm:
Prognostic factors are-nodal disease
,completeness of resection, and depth of
diaphragmatic invasion .
25. T4
⢠Heart and Great vessels: Rarely surgical
candidates
⢠Carina and Trachea: Carinal resection
⢠Ipsilateral pulmonary metastasis: Stage of
mediastinal node is key prognostic factor
⢠Vertebral body: Hemi/Total vertebral body
resection
⢠Esophagus:Unresectable
26. N0&N1
⢠In patients with N0-1 disease type of pulmonary
resection depend upon T category
⢠Intraoprative interlobar or hilar nodal assessment
is critical in decision making for sublobar
resection. VATS has role in it.
⢠N0NSCLC with local tumor invasion (T3):Extended
en bloc resection such as pneumonectomy
/sleeve resection/chest wall resection
⢠Cisplatin based adjuvant chemotherapy shows
improved survival in N1/NO and >T1b tumor
27. N2
⢠Chemoradiation + surgery
⢠N2 found on pretreatment staging:
â Bulky, multistation ,cytologically proven
:Chemoradiotherapy: Monoclonal antibodies
â Nonbulky, single station: Curative surgical resection
Neoadjuvant chemo. has role .
⢠N2 found at thoracotomy: Aborting Lung resection
followed by Induction therapy possibly followed by
lung resection or lung resection followed by adjuvant
therapy.
28. N3
⢠C/L mediastinal LN metastases are considered
a C/I for surgery because long term outcome
with surgery has been dismal.
⢠0% 3 year survival rate for patient with NSCLC
who underwent induction chemoradiotherapy
followed by surgery.
⢠Should be treated nonsugically
29. M1a and M1b
⢠M1a:Additional nodule in
C/L lung: Median survival 10
month
⢠5yr survival rate 3%
⢠FDG PET sensitive for
malignent metastatic
disease
⢠When double primaries
without mediastinal
disease, the optional
treatment is two stage
lobectomy for C/L lung
⢠Malignent pleural effusion:
C/I for surgery
⢠M1b:Adrenal gland:
Complete surgical resection
of both can improve survival
⢠Brain:30-50% patients
⢠Resection of solitary brain
metastases in a patient with
completely resected NSCLC
carry a potential cure rate
⢠Use of WBR (Whole brain
radiation)alone or with
surgery also have a role
⢠Stereotactic radiosurgery
another alternative along
with chemoradiotherapy
30. Treatment of SCLC
⢠Stages I-III disease :Chemoradiation
⢠Stage IV disease : chemotherapy only
cisplatin
carboplatin
cyclophosphamide
Surgery:1. For small peripheral tumor without nodal
involvement
2.Local control compaired with
chemoradiotherapy
3.Mixed histology tumor
4.Salvage surgery
31. Minimally invasive approaches
⢠INDICATIONS
⢠Similar to lobectomy using
open approach
⢠Clinical stage-I
⢠Age>70 yrs
⢠CONTRAINDICATIONS
⢠Inability to achieve
complete resection
⢠T3 or T4 tumor
⢠Active N2 or N3 disease
⢠Inability to achieve single-
lung ventilation.
⢠Tumor in lobar orifice at
bronchoscopy
⢠Complex ,calcified benign
hilar lymphadenopathy
⢠Prior thoracic irradiation
⢠Prior thoracic surgery
32. Strategy for Thoracoscopic lobectomy
⢠Single lung anesthesia using double lumen ET tube or
bronchial blocker
⢠Position: Full lateral decubitus with slight flexion at the
level of hip
⢠1st incision :7th or 8th ICS in MAL for thoracoscope (10mm
port access).For Ant.-Sup. hilum visualization
⢠2nd incision:5h or 6th ICS just inf. to breast(4,5-6mm ant.
access incision)
⢠30*/45* angled scope /flexile scope can be used
⢠Thorcoscopic staplers for control of vessel, bronchus,
fissure
⢠Wedge resection performed using an automatic stapling
device
33. Specific technical considerations
⢠L.U Lobectomy
⢠Left sup. Pulmonary vein
identified
⢠Pulmonary artery mobilized
⢠Left upper lobe bronchus is
visualized which may be
stapled and divided.
⢠Branches of pos. and
lingular arteries are stapled.
⢠R.U Lobectomy
⢠Slightly more difficult
⢠SPV identified and
mobilized
⢠UL branches are encircled
⢠PA mobilized, truncus
anterior may then be
stapled and divided
⢠Rt . Bronchus exposed and
upper lobe bronchus may
be stapled and divided
⢠Post. Ascending arterial
branch is stapled
34. ⢠R.M Lobectomy
⢠SPV identified and
mobilized
⢠Middle lobe vein is
encircled and stapled
⢠Expose middle lobe
bronchus and atrery
⢠Artery is stapled and
divided
⢠Lower Lobectomy(R orL)
⢠Lung is retracted
anteriorly
⢠Incise the pleura over
the IPV, which then be
encircled and stapled
⢠Lower lobe bronchus,
arterial trunk encircled
and stapled
⢠Fissure is completed
35. ⢠Segmentectomy
⢠In patients with poor lung
function or synchronous
primary tumors
⢠Small ,peripheral tumor
⢠Through thoracosope
⢠Wedge resection
⢠In pt. with small
peripheral tumor who will
not tolerate anatomic
resection
⢠ND:YAG laser and
monopolar floating ball
device
⢠VATS wedge resection of
small peripheral nodule
carried out using
endoscopic stapling
device
36. Multimodal Therapy
⢠Adjuvant therapy
Chemo/radiotherapy
⢠Induction therapy
⢠Guidelines
⢠Staging must include a through
search for distant metastatic
disease.
⢠Endoscopic and endobronchial
staging modalities more
refined
⢠Chemotherapy should revolve
around a platinum based
regimen
⢠More benefit with intended
dose of chemotherapy
⢠Adjuvant chemotherapy for
larger IB /II/III NSCLC
37. Surgical strategies for tumors invading the chest wall
⢠Demographics and
symptoms
⢠7TH Decade
⢠Incidence and mortality
High in men
⢠Chest pain-40-60%
⢠Recurrent LRTI-10-25%
⢠Weight loss-10-18%
⢠Hemoptysis-12%
⢠Dyspnea-11%
⢠Cough-11%
⢠Asymptomatic-25%
⢠Diagnosis
⢠Chest roentgenography
⢠Rib destruction
⢠Transthoracic needle
aspiration
⢠CT, MRI, Bone scan, PET
38. ⢠Staging
⢠Combind CT-PET scan
⢠MRI brain
⢠Surgical pathologic
staging (T,N,M)
⢠Role of EBUS âguided FNA
⢠Navigational
bronchoscopy
⢠Treatment
⢠N2- Induction
chemotherapy
⢠Surgery when objective
response to
chemotherapy and whose
disease can be completely
resected
⢠Progression even on
chemotherapy âno
surgery
39. ⢠Preoperative assessment
⢠Physiologic testing for
cardio-pulmonary reserve
⢠Management of DM and
nutritional support
⢠Phrenic nerve and
diaphragmatic involvemet
⢠Operative techniques
⢠Epidural catheter
⢠Double lumen tube
⢠PL thoracotomy
⢠Anterior neck approach
⢠For large tumor: use
stapler
⢠When adhesions: Extra
pleural dissection
40. ⢠Reconstruction
⢠Controversial
⢠All full thickness skeletal
defect that have the
potential for paradox
⢠Size ,location of resection
guide the decision
⢠Midthoracic pot. defect
⢠Fascia lata graft ,muscle
transposition, LD ,PM, RA,
SA, Trapezius, deltoid,TRAM
flap, PTFE,PPMM
⢠Postoperative care
⢠Tailored to individual
patient
⢠Decision on extubation
⢠Epidural anesthesia
⢠Chest tube removed on 7th
day
⢠Antibiotics only for 24 hours
41. ⢠Complications
⢠Seroma
⢠Wound infection
⢠Respiratory mechanical
changes
⢠Pathology and Results
⢠R0,R1,R2 Resection
⢠Depth of chest wall
invasion
⢠Opretive mortality is
with in 30 days of
surgery
⢠Results varies from
centre to centre
42. Anterior Approach to Superior sulcus lesions
⢠Presentation
⢠<5% of NSCLC
⢠Upper lobe ,invades
parietal pleura, Fascia,
brachial plexus,1st
rib,platysema
⢠Pulmonary symptoms
uncommon
⢠Abnormal sensation,pain
in axilla and medial
aspect of upper arm
⢠Overt pancoast syndrome
⢠Preoperative studies
⢠Assess for operability
⢠Diagnosis by :clinical
examination, X-ray,
bronchoscopy, sputum
cytology, FNA biopsy
⢠Tissue diagnosis: video
assisted thoracoscopy
43. Anterior transcervical technique
⢠One lung anesthesia with
urine output
mesurement, body temp.
mesurement
⢠Position: supine with neck
hyperextended and head
turned away from
involved site
⢠Incision: L-shaped
cervicotomy including
vertical pre-
sternoceidomastoid
incision
⢠Inferior belly of omohyoid
divided scalene fat pad is
dissected and sent for
pathology examination
⢠Division of sternothyroid
and sternohyoid
⢠Subclavian artery is
dissected
⢠Chest wall resection is
completed before the
upper lobectomy
⢠Three level laminectomy
45. Prognosis
⢠Prognostic factors for lung cancer
NSCLC:
Stage at presentation
Performance score
Weight loss
SCLC:
Stage at presentation
Performance score
Weight loss
Elevated LDH
Male sex
Hyponatremia
Elevated ALP
46. Screening
⢠Chest radiograph
⢠C.T scan
⢠LDCT: low density C.T
⢠NLST: National lung
screening trial
⢠ACS: American cancer
society
⢠ACCP: American college
of chest physician
⢠NCCN: National
comprehensive cancer
network
⢠USPSTF:U.S. Preventive
services task force